Bayhorse Silver Receives Final Bayhorse Silver Mine IP Survey Results, Extends Bayhorse Potential Mineralized Zone To Over 600 M, Identifies First IP Drill Target March 31, 2025 9:29 AM EDT | Source: Bayhorse Silver Inc. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/5015/246716_3e460840e42b6900_001full.jpg Bayhorse CEO Graeme O'Neill comments that, "the close proximity of the three new IP targets on strike east of the historic Sunshine, Junction and Big Dog ...

Group 1 - Global crude oil prices are experiencing a decline, with Brent crude down 15% year-on-year and showing negative returns so far in 2025 [1] - Despite the drop in oil prices, the global Energy sector has outperformed US large-cap stocks in recent months [1]

Core Insights - Brii Biosciences Limited announced new data from its Phase 2 ENSURE study at the APASL 2025 meeting, highlighting the potential of its therapies for chronic HBV infection [1][5] Study Design and Objectives - The ENSURE study is a multicenter, open-label Phase 2 trial designed to evaluate the efficacy of elebsiran in combination with pegylated interferon alpha (PEG-IFNα) in chronic HBV patients [2] - Cohort 4 included participants who previously received BRII-179, a therapeutic vaccine, to assess the combination treatment's effectiveness [2] Key Findings - In Cohort 4, 55.6% of BRII-179 responders achieved HBsAg seroclearance at Week 24, compared to only 10% in non-responders, indicating BRII-179's potential as a predictive tool for treatment response [3][10] - Data from Cohorts 1-3 showed higher rates of HBsAg loss and seroconversion in participants receiving elebsiran with PEG-IFNα compared to those receiving PEG-IFNα alone [4][11] Expert Commentary - Dr. Grace Lai-Hung Wong emphasized that the positive results from Cohort 4 support the potential of BRII-179 in identifying patients likely to respond to curative therapies [5] - David Margolis, MD, noted that the findings reinforce the strategy of using BRII-179 to enhance functional cure rates while minimizing unnecessary treatment costs for less responsive patients [5] Broader Context - Chronic HBV infection affects over 254 million people globally, with significant mortality rates, particularly in regions like China where 87 million are chronically infected [9] - BRII-179 is a novel immunotherapeutic candidate designed to enhance immune responses against HBV, and it has received Breakthrough Therapy Designation from the CDE in China [9][10] Future Directions - Brii Bio is advancing multiple combination studies involving BRII-179 and elebsiran, with key data expected to be presented at scientific conferences throughout 2025 [8][10]

Core Insights - Property & Casualty insurance stocks have remained resilient while the broader Financials sector has faced challenges over the past two months, indicating a potential investment opportunity in this niche [1] Group 1: Market Performance - The performance of Property & Casualty insurance stocks contrasts with the broader Financials sector, which has been under pressure [1] - Extreme weather events, including Hurricanes Helene and Milton, LA wildfires, and a severe cold snap in January, have influenced the market dynamics for these insurance stocks [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Target Corporation common stock between August 26, 2022, and November 19, 2024, of the April 1, 2025, lead plaintiff deadline for a class action lawsuit related to misleading statements made by Target regarding its ESG and DEI initiatives [1][4]. Group 1: Class Action Details - Investors who bought Target stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][6]. - The lead plaintiff must file a motion with the court by April 1, 2025, to represent other class members in the litigation [2]. Group 2: Allegations Against Target - The lawsuit claims that Target misled investors with false statements about its ESG and DEI mandates, which led to significant customer boycotts following the 2023 LGBT-Pride Campaign [4]. - The negative impact of the Campaign resulted in a decline in Target's stock price and sales falling for the first time in six years [5]. - It is alleged that Target's CEO and Board did not disclose known risks associated with the 2023 and 2024 Campaigns, leading to investors purchasing stock at artificially inflated prices [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Target Corporation common stock between August 26, 2022, and November 19, 2024, of the April 1, 2025, deadline to become a lead plaintiff in a class action lawsuit due to misleading statements made by Target regarding its ESG and DEI initiatives, which led to significant stock price declines [1][4][5]. Group 1: Class Action Details - Investors who bought Target stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][6]. - The deadline to move the Court to serve as lead plaintiff is April 1, 2025, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Case Background - The lawsuit alleges that Target misled investors with false statements about its ESG and DEI mandates, particularly following the backlash from its 2023 LGBT-Pride Campaign, which resulted in customer boycotts and a decline in sales for the first time in six years [4][5]. - The CEO and Board of Directors reportedly failed to disclose known risks associated with the 2023 and 2024 campaigns, leading to investors purchasing stock at inflated prices [5]. - The lawsuit claims that when the true details became public, investors suffered damages due to the decline in stock price [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a leading figure in the plaintiffs' bar [3].

Core Viewpoint - Target Inc. presents a unique investment opportunity as its stock price has dropped to levels not seen since the COVID-19 pandemic, offering a favorable risk-to-reward ratio for investors moving forward into the year [1][2]. Stock Performance and Forecast - Target's current stock price is $106.49, representing a 34.66% upside potential with a 12-month price forecast of $143.40, based on 31 analyst ratings [3]. - The stock has experienced a bearish decline of 20% year-to-date, now trading at 58% of its 52-week high, suggesting that negative news may already be priced in [3][4]. Market Sentiment and Institutional Investment - Analysts from Oppenheimer maintain an Overweight rating on Target, with a price target of $150, indicating a potential rally of 42.3% from current levels [6]. - Institutional investors have shown confidence in Target, with up to $4 billion in capital invested over the past quarter, led by UBS Asset Management, which increased its holdings by 14.4% [10][11]. Dividend and Financial Metrics - Target offers a dividend yield of 4.21%, with an annual dividend of $4.48, and a strong track record of 54 years of dividend increases, making it attractive for income-focused investors [8]. - The stock trades at a price-to-earnings (P/E) ratio of 11.3, significantly lower than the retail sector average of 24.0, indicating a substantial discount [12]. Defensive Investment Appeal - As market volatility increases, Target's status as a defensive investment in the supermarket sector may attract capital, especially given its current discounted valuation [12][13].

Core Viewpoint - Target Hospitality Corp. reported fourth-quarter 2024 results with earnings and revenues exceeding Zacks Consensus Estimates, although both metrics declined year-over-year [1][3]. Financial Performance - Adjusted EPS for the quarter was 12 cents, surpassing the Zacks Consensus Estimate of 6 cents, but down from 29 cents in the prior-year quarter [3]. - Total revenues reached $83.7 million, exceeding the consensus estimate of $80 million by 4.5%, but reflecting a 33.7% decline year-over-year [3]. Segment Analysis - Government segment revenues were $43.7 million, down from $87.5 million in the year-ago quarter, with adjusted gross profit of $37.7 million compared to $65.7 million previously [4]. - Hospitality & Facilities Services - South segment revenues increased slightly to $36.7 million from $36.2 million year-over-year, with adjusted gross profit of $12.6 million compared to $12.4 million [5][6]. - All Other segment revenues rose to $3.3 million from $2.5 million in the prior-year quarter [6]. Operational Highlights - Average utilized beds increased to 5,474 from 5,105 year-over-year, while the average daily rate decreased to $72.14 from $76.58 [6]. - Selling, general and administrative expenses were $12.6 million, up from $12.2 million in the prior-year period [7]. - Net income for the quarter was $12.5 million, down from $37.8 million in the prior-year quarter, and adjusted EBITDA was $41.1 million compared to $67.7 million previously [7]. Balance Sheet - As of December 31, 2024, cash and cash equivalents stood at $190.7 million, an increase from $103.9 million as of December 31, 2023 [8]. Future Outlook - For 2025, the company anticipates revenues between $265 million and $285 million, with adjusted EBITDA expected in the range of $47 million to $57 million [9].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to consider their financial situation and needs before relying on the information provided [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to perform their own research and understand the risks involved before making investment decisions [1].

Core Viewpoint - A class action lawsuit has been filed against Target Corporation for alleged violations of securities laws, specifically related to misleading statements about its ESG and DEI initiatives, which led to significant investor losses [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Target's securities between August 26, 2022, and November 19, 2024, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Target - The complaint alleges that Target made false and misleading statements regarding its ESG and DEI initiatives [4]. - The company faced significant backlash from customers over its LGBT-Pride Campaign, which included boycotts [4]. - As a result of these misleading statements, investors suffered damages when the truth about Target's situation became known [4].